コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 nocyte chemoattractant protein-1) and VLA-4 (very-late antigen-4).
2 r by chemokines leads to the inactivation of very late antigen 4.
5 e detected the active conformational form of very late antigen 4 after stimulation with a peptide mim
8 irway inflammation and was prevented by anti-very late antigen-4 and anti-interleukin-5 treatments, w
10 s of beta1 phosphorylation and a decrease in very late antigen 4 binding to its ligand vascular cell
11 imilar to, but more restricted than, current very late antigen-4-directed approaches that have signif
12 and natalizumab (Tysabri/Antegren) targeting very late antigen-4 for the treatment of relapsing-remit
13 ncrease expression of VCAM-1, a receptor for very late antigen-4 found on many hematopoietic progenit
14 dent mechanism to increase CD11c expression, very late antigen-4 function, and integrin coclustering
15 te function-associated antigen-1) and VLA-4 (very late antigen-4) is essential for T-cell trafficking
18 ction by 50%, whereas blocking L-selectin or very late antigen-4 showed significant but smaller effec
21 tes matrix metalloproteinase-9 secretion and very late antigen 4 (VLA-4)-mediated adhesion to vascula
26 hocytes that expressed low or high levels of very late antigen-4 (VLA-4) and non-antigen-specific act
27 rs to stromal cells is primarily mediated by very late antigen-4 (VLA-4) and vascular cell adhesion m
29 nction-associated antigen (LFA-1) and VCAM-1/very late antigen-4 (VLA-4) at select time points compar
30 rsor cells were transiently transfected with very late antigen-4 (VLA-4) binding to vascular cell adh
32 later, GVHD-associated increase in CD25 and very late antigen-4 (VLA-4) expression on donor T cells
33 lar endothelial growth factor receptor-1 and very late antigen-4 (VLA-4) have been shown to arrive at
34 ell adhesion molecule-1 (VCAM-1), LFA-1, and very late antigen-4 (VLA-4) have relatively little effec
35 esent study was to determine the role of the very late antigen-4 (VLA-4) integrin/ligand interaction
36 te function-associated antigen-1 (LFA-1) and very late antigen-4 (VLA-4) on adhesion of influenza hem
38 scular cell adhesion molecule 1 (VCAM-1) and very late antigen-4 (VLA-4) played an integral role in t
40 ion, we show that MBP-primed T cells express very late antigen-4 (VLA-4), and functional blocking ant
41 the adhesion molecules CD11a, CD11b, CD11c, very late antigen-4 (VLA-4), and L-selectin, as assessed
43 portance of VCAM-1, and its leukocyte ligand very late antigen-4 (VLA-4), in such leukocyte migration
45 he affinity of the alpha(4)beta(1) integrin, very late antigen-4 (VLA-4), measured with an LDV-contai
46 lasts within the bone marrow is adhesion via very late antigen-4 (VLA-4), the alpha(4)beta(1) integri
47 D49d), in complex with integrin beta1, forms very late antigen-4 (VLA-4), which interacts with vascul
48 cular cell adhesion molecule-1 (VCAM-1)- and very late antigen-4 (VLA-4)-mediated localization of CXC
51 une cells from patients under long-term anti-very late antigen-4 (VLA-4)/natalizumab therapy (LTNT) a
52 skin fibroblasts, making it unlikely that a very late antigen-4 (VLA-4)/VCAM-1 interaction is requir
54 duced by IL-3 in a dose-dependent manner via very late antigen-4 (VLA-4; alpha4beta1 integrins) and V
56 tion of the interaction between the integrin very-late antigen-4 (VLA-4; alpha 4 beta 1) and vascular
59 elated protein ligand, resulting in enhanced very late antigen-4 [VLA-4] directed adhesion and motili
61 To provide further insights into the anti-very late antigen 4 (VLA4)/anti-vascular cell adhesion m
62 ascular cell adhesion molecule-1 (VCAM1) and very late antigen-4 (VLA4) using monoclonal antibodies.
63 cule antagonist, compound A, to nonactivated very late antigen-4 (VLA4) was examined in lung inflamma
64 BL1(+) progenitors had similar expression of very late antigen-4 (VLA4), VLA5, leukocyte functional a
65 al cells, and mild expression of its ligand, very late antigen-4, was apparent in perivascular lympho
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。